BioSpace News Archive

Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study

InterVenn Biosciences today announced Regina Benjamin, MD, MBA, has joined the Company’s Board of Advisors, effective March 25, 2021. Dr. Benjamin joins the InterVenn Board of Advisors with extensive experience in prevention and population health.

Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA™ Institute for Human Data Science.

Human genetics and genomics contributed $265 billion to the U.S. economy in 2019 and has the potential to drive significant further growth given major new areas of application, according to a new report issued by the American Society of Human Genetics.

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that on May 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 22,775 shares of the company’s common stock to 11 newly-hired employees.

- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving placebo plus stable background therapy during the 24-week placebo-controlled period who were re-randomized to sotatercept plus stable background therapy during weeks 24 to 48 experienced improvements

Docbot, Inc ., an artificial intelligence (AI) technology company focusing on gastrointestinal (GI) disease, today announced the following upcoming oral presentation at Digestive Disease Week (DDW) 2021 , which takes place virtually May 21-23, 2021.

– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases – - Company-hosted investor and analyst conference call and webcast with guest PAH key opinion leader to be held today, Wednesday, May 19th at 10:30 a.m. EDT –

Company appoints biotech industry experts Stacie Peacock Shepherd, M.D., Ph.D., as Chief Medical Officer and Nora Brennan as Chief Financial Officer Biopharma executive Meenu Chhabra joins Board of Directors, will serve as Audit Chair

Industry veteran departs bioMérieux to lead the commercialization of Qvella’s lineup of products starting with FAST-Prep, an automated cartridge-based system for Positive Blood Culture (PBC) processing